Suppressive immune checkpoints such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) can be exploited either directly or indirectly by tumour cells to avoid elimination by the anti-tumour immune response. This evidence concerns the gene CTLA4 and neoplasm.